Adata partners with Itochu Corporation to strengthen presence in Japan’s memory market
On February 27th, Adata announced the formalization of a strategic partnership with Itochu Corporation, a prominent Japanese conglomerate, and its…
Meta propels smart glasses surge, but market differentiation wanes
Smart glasses took center stage at CES 2025. Counterpoint Research projects a 210% surge in global shipments this year, fueled…
Philippines-based Ayala retains Integrated Micro-Electronics amid profitability outlook
According to Bloomberg, Philippines-based Ayala Corp. decided to retain Integrated Micro-Electronics Inc. (IMI), its contract manufacturing subsidiary, after previously considering…
Shopline unveils 2025 survival strategies for retailers
E-commerce solutions provider Shopline Technology has observed a slowdown in retail growth, with brands facing two key challenges: fragmented consumer…
Trump orders review of wood supply chain
Over the next year, various U.S. departments will assess whether tariffs, quotas or updated permitting processes could help limit the country’s reliance…
Voluntary Recall of Wild Coast Raw Boneless Free Range Chicken Formula Raw Pet Food Because of Possible Bird Flu Health Risk
Wild Coast LLC dba Wild Coast Raw of Olympia, WA is recalling lots of frozen Boneless Free Range Chicken Formula…
FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use
[03-03-2015] The U.S. Food and Drug Administration (FDA) cautions that prescription testosterone products are approved only for men who have…
FDA Roundup: February 28, 2025
The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.
FDA issues class-wide labeling changes for testosterone products
FDA issues labeling changes for all testosterone products following conclusion of ambulatory blood pressure monitoring studies and TRAVERSE trial,
Generic Drugs Program Activities Report – FY 2024 Monthly Performance
This report provides monthly activities metrics for the FDA Generic Drugs Program, outlining agency actions on abbreviated new drug applications.…